NRP1 and central nervous system cancer: Additionally, Nasarre et al. showed that targeting the transmembrane domain of Nrp1 via a small peptide inhibitor has the potential to slow glioma progression due to reductions in angiogenesis and proliferation in pre-clinical human xenograft and rat models [95].